Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Epidemiology of Cancer in Europe—What Are the Trends?

December 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of stomach cancer in all parts of Europe, but unfortunately, the increasing age of the European Union (EU) population is linked with an increasing number of cases of cancer in total, with large increases in the incidence of Hodgkin’s lymphoma and malignant melanoma. In the next 15 years the proportion of people age 65 or over is likely to rise from 15% to 17%, a rise that will be matched by a similar fall in the 15 to 64 age group.”

“Levels of lung cancer and other smoking related cancers are high and still increasing, particularly in central and eastern Europe,” continued Dr. Boyle. “An epidemic of lung cancer is threatening women in southern Europe and this will pose a major problem for health services in coming decades.”

Dr. Boyle makes a strong call to action: “With our current knowledge, we could eliminate at least half of all cancers. We need to take practical steps to do this, rather than just discuss it.” 

Articles in this issue

Breast Cancer Treatment in Europe
The Sidney Kimmel Foundation for Cancer Research Seeks 1998 Scholar Applicants
New Study Shows Processed Tomato Products Are a Better Source of Lycopene Than Fresh Tomatoes
New Endocrine Treatments for Prostate Cancer
FDA Grant Given to Continue Studies of Aminopterin
American Association for Cancer Research 1998 Research Fellowships
Breast Cancer: The Importance of Local Control
Screening for Prostate Cancer-The European View
Testosterone Levels Early in Life May Determine Later Risk of Prostate Cancer
The Surgeon and Surgical Procedure as Prognostic Factors
Clinical Trial of New Agent to Overcome MDR Resistance in Multiple Myeloma Patients
Epidemiology of Cancer in Europe—What Are the Trends?
Surgical Outcomes in Gastric Cancer
Combined-Modality Therapy for Head and Neck Cancer
Study Suggests Smoking Is Associated with Chromosome Loss
Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Related Content
Advertisement

Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Ariana Pelosci
May 13th 2025
Article

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


"SurVaxM’s excellent safety profile and tolerability to date also help optimize quality of life for patients with this highly aggressive cancer, where additional treatment options are direly needed," according to Ajay Abad, MD, of Roswell Park Comprehensive Cancer Center.

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Russ Conroy
May 12th 2025
Article

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.


67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Related Content
Advertisement

Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Ariana Pelosci
May 13th 2025
Article

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


"SurVaxM’s excellent safety profile and tolerability to date also help optimize quality of life for patients with this highly aggressive cancer, where additional treatment options are direly needed," according to Ajay Abad, MD, of Roswell Park Comprehensive Cancer Center.

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Russ Conroy
May 12th 2025
Article

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.


67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.